Literature DB >> 11350877

Intraoperative immunophotodetection for radical resection of cancers: evaluation in an experimental model.

M Gutowski1, M Carcenac, D Pourquier, C Larroque, B Saint-Aubert, P Rouanet, A Pèlegrin.   

Abstract

The aim of our study was to assess the technique of immunophotodetection (IPD) in intraoperative situations in an experimental model and to determine its capacity to detect very small tumor masses. IPD is a recent technology involving fluorescent dye-labeled monoclonal antibodies (MAbs) directed against tumor-associated antigens. Up to now, no intraoperative device for IPD has been developed, and limits of detection of the technique are unknown. MAb-dye conjugates were prepared using the anti-carcinoembryonic antigen MAb 35A7 labeled with indocyanine and (125)I. Time-dependent (6, 12, 24, 48, and 96 h post i.v. injection) and dose-dependent (10, 40, and 100 microg of conjugate) biodistribution studies were performed in nude mice bearing an LS174T peritoneal carcinomatosis demonstrating high tumor uptake (up to 21% of the injected dose/g of tumor 48 h postinjection). Intraoperative IPD was studied, using a newly developed device, in 16 mice 48 h after i.v. injection of 40 microg of the (125)I-MAb 35A7-indocyanine conjugate. The fluorescent status of 333 biopsies was compared with their histological analysis. Sensitivity was 90.7%, specificity was 97.2%, the positive predictive value was 94.7%, and the negative predictive value was 94.9%. Detection of very small nodules (<1 mg in weight or <1 mm in diameter) was possible. However, we observed a decrease in sensitivity as a function of tumor mass: 100% for nodules >10 mg versus 78% for nodules < or =1 mg. These experiments demonstrate that intraoperative IPD is easy to use and associated with high sensitivity and specificity, even for low tumor masses. On the basis of these encouraging results, intraoperative IPD should be assessed in a clinical study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350877

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  New horizons in colorectal cancer surgery.

Authors:  W J H J Meijerink; M H G M van der Pas; D L van der Peet; M A Cuesta; S Meijer
Journal:  Surg Endosc       Date:  2008-12-13       Impact factor: 4.584

2.  The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.

Authors:  Imed Salhi; Sylvie Cambon-Roques; Isabelle Lamarre; Daniel Laune; Franck Molina; Martine Pugnière; Didier Pourquier; Marian Gutowski; Jean-Yves Picard; Françoise Xavier; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

3.  Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets.

Authors:  Ruth Cohen; Marieke A Stammes; Inge Hc de Roos; Marijke Stigter-van Walsum; Gerard Wm Visser; Guus Ams van Dongen
Journal:  EJNMMI Res       Date:  2011-12-01       Impact factor: 3.138

4.  Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers.

Authors:  Véronique Garambois; Fabienne Glaussel; Elodie Foulquier; Marc Ychou; Martine Pugnière; Robin X Luo; Binyam Bezabeh; André Pèlegrin
Journal:  BMC Cancer       Date:  2004-10-15       Impact factor: 4.430

Review 5.  The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review.

Authors:  Michael A Turner; Thinzar M Lwin; Siamak Amirfakhri; Hiroto Nishino; Robert M Hoffman; Paul J Yazaki; Michael Bouvet
Journal:  Biomolecules       Date:  2021-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.